Cladribine (oral) and Leuprolide and norethindrone Intramuscular, Oral
Determining the interaction of Cladribine (oral) and Leuprolide and norethindrone Intramuscular, Oral and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives. MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. Cerner Multum, Inc. "Australian Product Information." O 0
Professional:ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.
MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: cladribine
Brand name: Mavenclad, Leustatin
Synonyms: Cladribine
Generic Name: leuprolide / norethindrone
Brand name: Lupaneta Pack
Synonyms: Leuprolide and norethindrone, Leuprolide and Norethindrone
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cladribine (oral)-Leuprolide Injection (CPP)
- Cladribine (oral)-Leuprolide Injection (Prostate)
- Cladribine (oral)-Leuprolide Injection (Women)
- Cladribine (oral)-Leuprolide Intramuscular, Subcutaneous, Intradermal, Injection
- Cladribine (oral)-Leustatin
- Cladribine (oral)-Leustatin injection
- Leuprolide and norethindrone Intramuscular, Oral-Cladribine injection
- Leuprolide and norethindrone Intramuscular, Oral-Cladribine Intravenous
- Leuprolide and norethindrone Intramuscular, Oral-Cladribine Tablets
- Leuprolide and norethindrone Intramuscular, Oral-Claforan
- Leuprolide and norethindrone Intramuscular, Oral-Claforan in D5W
- Leuprolide and norethindrone Intramuscular, Oral-Claravis